Published in Vaccine Weekly, July 30th, 2003
"Vaccines that elicit systemic and mucosal immune responses should be the choice to control human immunodeficiency virus (HIV) infections," stated M. Magdalena Gherardi and colleagues at the Centro Nacional de Biotecnologia in Madrid, Spain. "We have previously shown that prime-boost immunizations with influenza virus Env...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.